Literature DB >> 26465402

Is a second cycle of immunoglobulin justified in axonal forms of Guillain-Barré syndrome?

Daniel Agustin Godoy1, Alejandro Rabinstein2.   

Abstract

Objective In certain situations, severe forms of Guillain-Barré syndrome (GBS) show no response or continue to deteriorate after intravenous immunoglobulin (IVIg) infusion. It is unclear what the best treatment option would be in these circumstances.Method This is a case report on patients with severe axonal GBS in whom a second cycle of IVIg was used.Results Three patients on mechanical ventilation who presented axonal variants of GBS, with autonomic dysfunction, bulbar impairment and Erasmus score > 6, showed no improvement after IVIg infusion of 400 mg/kg/d for 5 days. After 6 weeks, we started a second cycle of IVIg using the same doses and regimen as in the previous one. On average, 5 days after the second infusion, all the patients were weaned off mechanical ventilation and showed resolution of their blood pressure and heart rate fluctuations.Conclusions A second cycle of IVIg may be an option for treating severe forms of GBS.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26465402     DOI: 10.1590/0004-282X20150136

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  5 in total

1.  Are Repeated Cycles of Intravenous Immunoglobulin Justified in Patients With Poorly Responsive Guillain-Barré Syndrome?

Authors:  Hussein Algahtani; Bader Shirah; Khalid Alrefaei; Mohammed Albassam; Nawal Abdelghaffar
Journal:  Neurohospitalist       Date:  2019-12-13

2.  Disturbance of Plasma Lipid Metabolic Profile in Guillain-Barre Syndrome.

Authors:  Hsiang-Yu Tang; Daniel Tsun-Yee Chiu; Jui-Fen Lin; Cheng-Yu Huang; Kuo-Hsuan Chang; Rong-Kuo Lyu; Long-Sun Ro; Hung-Chou Kuo; Mei-Ling Cheng; Chiung-Mei Chen
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

3.  Intravenous Immunoglobulin for Severe Protracted Pediatric Guillain-Barre Syndrome: Is Single Dose Adequate?

Authors:  Priyanka Madaan; Prashant Jauhari; N M Shruthi; Biswaroop Chakrabarty; Sheffali Gulati
Journal:  Ann Indian Acad Neurol       Date:  2019 Jan-Mar       Impact factor: 1.383

4.  Rescue treatment in patients with poorly responsive Guillain-Barre syndrome.

Authors:  Ayman Mahmoud Alboudi; Pournamy Sarathchandran; Samar Sameer Geblawi; Deeb Maxwell Kayed; Jihad Inshasi; Sadhik Puthan Purayil; Abu Baker Almadani; Bashar Katirji
Journal:  SAGE Open Med       Date:  2019-03-25

Review 5.  Severe Guillain-Barré syndrome associated with chronic hepatitis B: A case report and literature review.

Authors:  Jiajun Wei; Shenhan Duan
Journal:  Medicine (Baltimore)       Date:  2021-12-03       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.